Business Context and Reporting Period
This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of September 2018, with a specific reporting date of September 12, 2018. The registrant is a foreign private issuer incorporated in Belgium, headquartered in Mechelen. The filing serves to incorporate by reference a press release dated September 12, 2018 (Exhibit 99.1) into the company's active registration statements.
Financial Metrics
The provided filing text contains no financial data. It does not report revenue, profit, cash flow, margins, debt, or liquidity figures. The document is a procedural filing to distribute a press release and does not include a financial statement or performance summary.
Material Changes
The filing text does not disclose specific material changes in financial position or operations. It solely references the issuance of a press release on September 12, 2018, the content of which is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These elements would be contained within the attached Exhibit 99.1 (the press release), which is not part of the input text provided for analysis.
Key Facts for Investor Verification
- Company Identity: Verify that the filing pertains to Galapagos NV, not Lakefront Biotherapeutics NV.
- Content Source: The substantive information regarding the September 12, 2018 event is located in Exhibit 99.1, which is referenced but not included in this text.
- Registration Impact: The press release is incorporated by reference into multiple active registration statements (Forms F-3 and S-8).
- Financial Data: No financial metrics are available in this specific document; investors must consult the company's Form 20-F or the full press release for financial details.